The first patient has been dosed in an ongoing phase 1/2a clinical trial with a new thaw-and-inject formulation of OpRegen, delivered with the Orbit subretinal delivery system, BioTime announced in a press release.
The open-label, dose escalation trial will evaluate the safety and efficacy of OpRegen, a human embryonic stem cell-derived retinal pigment epithelium transplant therapy, in patients with dry age-related macular degeneration.
“We are excited to be evaluating the FDA-cleared Orbit SDS in the next six patients of our phase 1/2a study,” Brian M. Culley, BioTime CEO, said in
Uncategorized